CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
基于微流控的剂量可控胞内 mRNA 递送平台实现的 CAR-T 细胞嵌合抗原受体滴定
英文原题：Titering of Chimeric Antigen Receptors on CAR T Cells enabled by a Microfluidic-based Dosage-Controlled Intracellular mRNA Delivery Platform.
查看英文原题
Titering of Chimeric Antigen Receptors on CAR T Cells enabled by a Microfluidic-based Dosage-Controlled Intracellular mRNA Delivery Platform.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 在癌症治疗、特别是B细胞急性淋巴细胞白血病等血液肿瘤中取得前所未有的疗效，当前也在拓展至其他血液肿瘤和实体瘤，但可能出现危及生命的意外副作用。本研究提出一种声学-电学微流控平台，通过均匀混合和操控细胞膜，使每个T细胞获得近似相同剂量的CAR编码mRNA。研究还显示，可通过改变输入功率调节原代T细胞表面CAR表达密度。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy shows unprecedented efficacy for cancer treatment, particularly in treating patients with various blood cancers, most notably B-cell acute lymphoblastic leukemia (B-ALL). In recent years, CAR T-cell therapies are being investigated for treating other hematologic malignancies and solid tumors. Despite the remarkable success of CAR T-cell therapy, it has unexpected side effects that are potentially life threatening.
Here, we demonstrate the delivery of approximately the same amount of CAR gene coding mRNA into each T cell propose an acoustic-electric microfluidic platform to manipulate cell membranes and achieve dosage control via uniform mixing, which delivers approximately the same amount of CAR genes into each T cell.
We also show that CAR expression density can be titered on the surface of primary T cells under various input power conditions using the microfluidic platform.
论文信息
- 作者
- Chen YH、Jiang R、Lee AP
- 文献类型
- 预印本
- 期刊
- bioRxiv : the preprint server for biology2023 Mar 15
- 原文标识
- PubMed 36993279 · DOI 10.1101/2023.03.14.532624